About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Podcasts
Discussing RA: MACE, VTE, and malignancy in filgotinib RA and UC patients, and MACE related to JAKis
Publications
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial
Publications
Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes
Publications
Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions
Publications
Efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with moderate to severe rheumatoid arthritis and an inadequate response to methotrexate
Podcasts
Webinar Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA
Publications
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
Publications
Which is the best option for axSpA patients after first TNFi failure: switch to secukinumab or cycling with other TNFi?
Publications
Major adverse cardiovascular events related to JAK inhibitors: A disproportionality analysis using the WHO Global Individual Case Safety Database
Publications
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis
Publications
The concept of difficult-to-treat disease in rheumatology: where next?
Publications
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomised placebo-controlled PROTOSTAR study
Podcasts
Discussing PsA: JAKi Comparative safety and Burden and determinants of multi‑b/tsDMARD failure in PsA
Podcasts
Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive first-line DMARDs
Podcasts
Author Interview: Professor Phillip Helliwell, March 2025
Podcasts
Author Interview: Professor Philip Helliwell, 2025
Publications
Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development
Publications
Burden and determinants of multi-b/tsDMARD failure in psoriatic arthritis
Publications
Effective second‑line b/tsDMARDs for patients with rheumatoid arthritis unresponsive to first‑line b/tsDMARDs from the FIRST registry
Publications
Effectiveness of JAK Inhibitors Compared with Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results from a Nationwide Swedish Cohort Study
Publications
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial
Publications
Interleukin‑23 versus Interleukin‑17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real‑World Comparison From the TriNetX US Collaborative Network
Podcasts
Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity
Publications
Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: An open-label extension of randomized clinical trials
Podcasts
Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis
Podcasts
Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2
Podcasts
Author Interview: Professor Denis McGonagle, 2025
Publications
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
Publications
Achievement of endoscopic remission after induction reduces hospitalization burden in Crohn’s Disease: findings from a pooled post hoc analysis of risankizumab and upadacitinib Phase III trials
Publications
Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis
Publications
Bimekizumab improves patient-reported outcomes and work productivity in patients with psoriatic arthritis: 1-Year results from two Phase 3 studies
Publications